Asad Haider
Stock Analyst at Goldman Sachs
(4.68)
# 930
Out of 4,662 analysts
127
Total ratings
89.1%
Success rate
25.8%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintained: Buy | $140 | $152.20 | -8.02% | 21 | Aug 19, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,283 → $1,367 | $1,280.34 | +6.77% | 24 | Aug 6, 2026 | |
| RPRX Royalty Pharma | Maintained: Buy | $59 → $66 | $61.73 | +6.92% | 4 | Aug 6, 2026 | |
| PFE Pfizer | Maintained: Hold | $26 | $28.24 | -7.93% | 20 | Aug 4, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Buy | $282 | $273.41 | +3.14% | 23 | Aug 3, 2026 | |
| ABBV AbbVie | Maintained: Hold | $244 | $265.97 | -8.26% | 8 | Jul 21, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintained: Hold | $61 | $67.61 | -9.78% | 11 | Jul 20, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintained: Hold | $37 → $38 | $28.53 | +33.19% | 4 | May 7, 2026 | |
| INVA Innoviva | Maintained: Sell | $17 → $18 | $21.48 | -16.20% | 2 | May 6, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $132 → $133 | $113.12 | +17.57% | 5 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $38 → $67 | $63.30 | +5.85% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $442.36 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $11.03 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $168 | $172.49 | n/a | 1 | Dec 14, 2018 |
Merck & Co.
Aug 19, 2026
Maintained: Buy
Price Target: $140
Current: $152.20
Upside: -8.02%
Eli Lilly and Company
Aug 6, 2026
Rated: Buy
Price Target: $1,283 → $1,367
Current: $1,280.34
Upside: +6.77%
Royalty Pharma
Aug 6, 2026
Maintained: Buy
Price Target: $59 → $66
Current: $61.73
Upside: +6.92%
Pfizer
Aug 4, 2026
Maintained: Hold
Price Target: $26
Current: $28.24
Upside: -7.93%
Johnson & Johnson
Aug 3, 2026
Reiterated: Buy
Price Target: $282
Current: $273.41
Upside: +3.14%
AbbVie
Jul 21, 2026
Maintained: Hold
Price Target: $244
Current: $265.97
Upside: -8.26%
Bristol-Myers Squibb Company
Jul 20, 2026
Maintained: Hold
Price Target: $61
Current: $67.61
Upside: -9.78%
NewAmsterdam Pharma Company
May 7, 2026
Maintained: Hold
Price Target: $37 → $38
Current: $28.53
Upside: +33.19%
Innoviva
May 6, 2026
Maintained: Sell
Price Target: $17 → $18
Current: $21.48
Upside: -16.20%
BioNTech SE
May 5, 2026
Maintained: Buy
Price Target: $132 → $133
Current: $113.12
Upside: +17.57%
Feb 26, 2026
Maintained: Hold
Price Target: $38 → $67
Current: $63.30
Upside: +5.85%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $442.36
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $11.03
Upside: n/a
Dec 14, 2018
Maintained: Buy
Price Target: $168
Current: $172.49
Upside: n/a